Ascentage Pharma Group International (HK:6855) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascentage Pharma Group International is showcasing promising results from its drug candidates olverembatinib and lisaftoclax at the 2024 American Society of Hematology Annual Meeting. Olverembatinib, a third-generation BCR-ABL inhibitor, and lisaftoclax, a Bcl-2 inhibitor, are being highlighted for their potential in treating various hematologic conditions. This recognition underscores the company’s ongoing advancements in drug development, capturing the interest of investors looking for innovative therapies in the biotech sector.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.